Page last updated: 2024-11-13
ly2409021
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
adomeglivant: a glucagon receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 91933867 |
| CHEMBL ID | 3707351 |
| MeSH ID | M000610534 |
Synonyms (29)
| Synonym |
|---|
| 1488363-78-5 |
| adomeglivant, (-)- |
| ly-2409021 |
| 3-(4-((1s)-1-((4'-tert-butyl-2,6-dimethylbiphenyl-4-yl)oxy)-4,4,4- trifluorobutyl)benzamido)propanoic acid |
| adomeglivant [who-dd] |
| .beta.-alanine, n-(4-((1s)-1-((4'-(1,1-dimethylethyl)-2,6-dimethyl(1,1'-biphenyl)-4-yl)oxy)-4,4,4-trifluorobutyl)benzoyl)- |
| adomeglivant [usan] |
| adomeglivant [inn] |
| adomeglivant |
| 74Z5ZL2KVG , |
| ly2409021 |
| CHEMBL3707351 |
| unii-74z5zl2kvg |
| ly 2409021 |
| CS-5729 |
| HY-19904 |
| 3-[[4-[(1s)-1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]-4,4,4-trifluorobutyl]benzoyl]amino]propanoic acid |
| gtpl9479 |
| adomeglivant (usan) |
| D10861 |
| DB11704 |
| (s)-3-(4-(1-(4'-tert-butyl-2,6-dimethylbiphenyl-4-yloxy)-4,4,4-trifluorobutyl)benzamido)propanoic acid |
| Q27266313 |
| 3-(4-{(1s)-1-[(4'-tert-butyl-2,6-dimethylbiphenyl-4-yl)oxy]-4,4,4-trifluorobutyl}benzamido)propanoic acid |
| A858152 |
| F85410 |
| MS-30128 |
| fasltmsupqdlib-mhzltwqesa-n |
| AKOS040741049 |
Research Excerpts
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "LY2409021 treatment showed significant HbA1c reductions vs placebo (LS mean difference -0.77%; P < .001) but not sitagliptin (-0.20%; P = .383)." | ( Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes. Chalasani, N; Garhyan, P; Guzman, CB; Hardy, TA; Kazda, C; Liu, R; Pillai, SG; Regev, A; Shankar, S; Zhang, XM, 2017) | 1.53 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Serum aminotransferases increased in a dose-dependent manner with multiple dosing and reversed after cessation of dosing." | ( Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Deeg, MA; Fu, H; Garhyan, P; Kelly, RP; Lim, CN; Loh, MT; Pinaire, JA; Prince, MJ; Raddad, E, 2015) | 0.66 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (2)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| PPM1D protein | Homo sapiens (human) | Potency | 26.2123 | 0.0052 | 9.4661 | 32.9993 | AID1347411 |
| Interferon beta | Homo sapiens (human) | Potency | 26.2123 | 0.0033 | 9.1582 | 39.8107 | AID1347411 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (30)
Molecular Functions (5)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytokine activity | Interferon beta | Homo sapiens (human) |
| cytokine receptor binding | Interferon beta | Homo sapiens (human) |
| type I interferon receptor binding | Interferon beta | Homo sapiens (human) |
| protein binding | Interferon beta | Homo sapiens (human) |
| chloramphenicol O-acetyltransferase activity | Interferon beta | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (2)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular space | Interferon beta | Homo sapiens (human) |
| extracellular region | Interferon beta | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1345985 | Human glucagon receptor (Glucagon receptor family) | 2016 | Diabetes care, Jul, Volume: 39, Issue:7 | Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. |
| AID1345985 | Human glucagon receptor (Glucagon receptor family) | 2015 | Diabetes, obesity & metabolism, Apr, Volume: 17, Issue:4 | Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. |
| AID1418649 | Antihyperglycemic activity in db/db mouse assessed as reduction in blood glucose level at 50 mg/kg, po administered once per day for 4 weeks and measured after 12 hrs fasting | 2018 | Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21 | Design, synthesis, and effects of novel phenylpyrimidines as glucagon receptor antagonists. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (13)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 20.87
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.87) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 6 (46.15%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (53.85%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||